ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1495

How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Abstract Number: 1496

Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?
Abstract Number: 1497

How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
Abstract Number: 1498

The Association Between Sonographic Enthesitis with Sonographic Synovitis and Tenosynovitis in Psoriatic Arthritis
Abstract Number: 1499

The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
Abstract Number: 1500

Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry
Abstract Number: 1501

Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)
Abstract Number: 1502

Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams
Abstract Number: 1503

Is Inflammation-driven Bone Loss Associated with Two-year Bone Formation at the Same Vertebra in Axial Spondyloarthritis? – a Multilevel MRI and Low Dose CT Analysis from the Sensitive Imaging of Axial Spondyloarthritis (SIAS) Cohort
Abstract Number: 1504

Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement
Abstract Number: 1505

Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics
Abstract Number: 1506

Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study
Abstract Number: 1507

Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Outcome Measures in Psoriatic Arthritis
Abstract Number: 1508

Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
Abstract Number: 1509

Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].